This data repository contains several datasets supplementing the paper “Dissecting the cellular architecture of neuroblastoma bone marrow metastasis using single-cell transcriptomics and epigenomics unravels the role of monocytes at the metastatic niche” by Fetahu, Esser-Skala, Dnyansagar et al. (2023). snp_array.tgz: SNP array data R_data_generated.tgz: Files generated by the analysis scripts in the GitHub repository associated with the publication.This study was funded by the Vienna Science and Technology Fund (WWTF#LS18-111, to S.T.M., N.F., and R.L.), MAPMET (FWF#P35841-B, to S.T.M.) by the Austrian Science Fund and LIQUIDHOPE (FWF#I4162, to S.T.M.) by the Transcan-2/ERA-NET initiative, EPICODE (FWF#P35072 to I.S.F.) by the Austrian...
Existing marker-based methods of minimal residual disease (MRD) determination in neuroblastoma do no...
<p>(<b>A</b>) Four-group significance analysis for microarray (SAM) between healthy controls (H.1-3)...
Treatment options for patients with brain metastases (BMs) have limited efficacy and the mortality r...
This data repository contains several datasets supplementing the paper “Dissecting the cellular arch...
Dissecting the cellular architecture of neuroblastoma bone marrow metastasis using single-cell trans...
Abstract Metastasis is the major cause of cancer-related deaths. Neuroblastoma (NB), a childhood tum...
While the bone marrow attracts tumor cells in many solid cancers leading to poor outcome in affected...
Existing marker-based methods of minimal residual disease (MRD) determination in neuroblastoma do no...
Existing marker-based methods of minimal residual disease (MRD) determination in neuroblastoma do no...
Existing marker-based methods of minimal residual disease (MRD) determination in neuroblastoma do no...
Existing marker-based methods of minimal residual disease (MRD) determination in neuroblastoma do no...
Existing marker-based methods of minimal residual disease (MRD) determination in neuroblastoma do no...
Existing marker-based methods of minimal residual disease (MRD) determination in neuroblastoma do no...
Existing marker-based methods of minimal residual disease (MRD) determination in neuroblastoma do no...
Existing marker-based methods of minimal residual disease (MRD) determination in neuroblastoma do no...
Existing marker-based methods of minimal residual disease (MRD) determination in neuroblastoma do no...
<p>(<b>A</b>) Four-group significance analysis for microarray (SAM) between healthy controls (H.1-3)...
Treatment options for patients with brain metastases (BMs) have limited efficacy and the mortality r...
This data repository contains several datasets supplementing the paper “Dissecting the cellular arch...
Dissecting the cellular architecture of neuroblastoma bone marrow metastasis using single-cell trans...
Abstract Metastasis is the major cause of cancer-related deaths. Neuroblastoma (NB), a childhood tum...
While the bone marrow attracts tumor cells in many solid cancers leading to poor outcome in affected...
Existing marker-based methods of minimal residual disease (MRD) determination in neuroblastoma do no...
Existing marker-based methods of minimal residual disease (MRD) determination in neuroblastoma do no...
Existing marker-based methods of minimal residual disease (MRD) determination in neuroblastoma do no...
Existing marker-based methods of minimal residual disease (MRD) determination in neuroblastoma do no...
Existing marker-based methods of minimal residual disease (MRD) determination in neuroblastoma do no...
Existing marker-based methods of minimal residual disease (MRD) determination in neuroblastoma do no...
Existing marker-based methods of minimal residual disease (MRD) determination in neuroblastoma do no...
Existing marker-based methods of minimal residual disease (MRD) determination in neuroblastoma do no...
Existing marker-based methods of minimal residual disease (MRD) determination in neuroblastoma do no...
<p>(<b>A</b>) Four-group significance analysis for microarray (SAM) between healthy controls (H.1-3)...
Treatment options for patients with brain metastases (BMs) have limited efficacy and the mortality r...